Skip to main content
Premium Trial:

Request an Annual Quote

Decipher Biosciences: Robert Epstein, Kathy Hibbs

Decipher Biosciences has appointed Robert Epstein and Kathy Hibbs to its board of directors. Epstein was also elected as the firm's chairman.

Epstein is CEO and cofounder of Epstein Health. He also serves on the board of directors at Illumina, Fate Therapeutics, Veracyte, and Proteus Digital Health. Epstein previously served as president at Medco-UBC from 2010 to 2012. From 1997 to 2010, he held the role of Medco's chief medical officer. He has also served on the boards of directors of the Drug Information Association and the International Society of Quality of Life. In addition, he has served on the Centers for Disease Control and Prevention's Evaluation of Genomic Application in Practice & Prevention Stakeholder Committee, as well as on the Agency for Healthcare Research and Quality Centers for Education and Research on Therapeutics Committee.

Hibbs has served as chief legal and regulatory officer for 23andMe since 2014. She has also served as a member of the Fast Company Impact Council since April 2019 and as a member of the board of directors of Cadex Genomics since Oct 2019. Prior to 23andMe, she was senior VP and general counsel at Genomic Health.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.